AH-0109(AH-0109) - 药物靶点：RT_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

RT

作用机制

RT抑制剂(逆转录酶抑制剂)

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症-

非在研适应症

HIV感染

原研机构

University of Manitoba

在研机构-

非在研机构

University of Manitoba

最高研发阶段无进展临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C21H20ClN3O3S

InChIKeyLPANQYFEAHDOIP-UHFFFAOYSA-N

CAS号827013-98-9

关联

100 项与 AH-0109 相关的临床结果

登录后查看更多信息

100 项与 AH-0109 相关的转化医学

登录后查看更多信息

100 项与 AH-0109 相关的专利（医药）

登录后查看更多信息

1

项与 AH-0109 相关的文献（医药）

2013-08-01·Antimicrobial Agents and Chemotherapy2区 · 医学

Characterization of Antiviral Activity of Benzamide Derivative AH0109 against HIV-1 Infection

2区 · 医学

Article

作者: Wainberg, Mark A. ; Yao, Xiaojian ; Liu, ShuiPing ; Chen, Liyu ; Ao, Zhujun ; Wu, Guojun ; Jayappa, Kallesh Danappa ; Kobinger, Gary

ABSTRACT In the absence of an effective vaccine against HIV-1 infection, anti-HIV-1 strategies play a major role in disease control. However, the rapid emergence of drug resistance against all currently used anti-HIV-1 molecules necessitates the development of new antiviral molecules and/or strategies against HIV-1 infection. In this study, we have identified a benzamide derivative named AH0109 that exhibits potent anti-HIV-1 activity at an 50% effective concentration of 0.7 μM in HIV-1-susceptible CD4 + C8166 T cells. Mechanistic analysis revealed that AH0109 significantly inhibits both HIV-1 reverse transcription and viral cDNA nuclear import. Furthermore, our infection experiments indicated that AH0109 is capable of disrupting the replication of HIV-1 strains that are resistant to the routinely used anti-HIV-1 drugs zidovudine, lamivudine, nevirapine, and raltegravir. Together, these findings provide evidence for a newly identified antiviral molecule that can potentially be developed as an anti-HIV-1 agent.

100 项与 AH-0109 相关的药物交易

登录后查看更多信息